Literature DB >> 18032664

Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice.

Edward C Stack1, Alpaslan Dedeoglu, Karen M Smith, Kerry Cormier, James K Kubilus, Mikhail Bogdanov, Wayne R Matson, Lichuan Yang, Bruce G Jenkins, Ruth Luthi-Carter, Neil W Kowall, Steven M Hersch, M Flint Beal, Robert J Ferrante.   

Abstract

Huntington's disease (HD) is an autosomal dominant inherited neurodegenerative disorder in which the neostriatum degenerates early and most severely, with involvement of other brain regions. There is significant evidence that excitotoxicity may play a role in striatal degeneration through altered afferent corticostriatal and nigrostriatal projections that may modulate synaptically released striatal glutamate. Glutamate is a central tenant in provoking excitotoxic cell death in striatal neurons already weakened by the collective molecular events occurring in HD. In addition, transcriptional suppression of trophic factors occurs in human and transgenic mouse models of HD, suggesting that a loss of trophic support might contribute to degeneration. Since anti-glutamate approaches have been effective in improving disease phenotype in HD mice, we examined whether deafferentation of the corticostriatal and nigrostriatal pathways may mitigate striatal stress and neurodegeneration. Both surgical and chemical lesions of the corticostriatal and nigrostriatal pathways, respectively, improved the behavioral, neuropathological, and biochemical phenotype in R6/2 transgenic mice and extended survival. Decortication ameliorated hindlimb clasping, striatal neuron atrophy, and huntingtin-positive aggregates, improved N-acetyl aspartate/creatine levels, reduced oxidative stress, and significantly lowered striatal glutamate levels. In addition, 6-hydroxydopamine lesioned mice showed extended survival along with a significant reduction in striatal glutamate. These results suggest that synaptic stress is likely to contribute to neurodegeneration in HD, whereas transsynaptic trophic influences may not be as salient. Thus, modulation of synaptic influences continues to have therapeutic potential in HD.

Entities:  

Mesh:

Year:  2007        PMID: 18032664      PMCID: PMC6673303          DOI: 10.1523/JNEUROSCI.4318-07.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  32 in total

1.  Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models.

Authors:  Melissa J Leyva; Francesco Degiacomo; Linda S Kaltenbach; Jennifer Holcomb; Ningzhe Zhang; Juliette Gafni; Hyunsun Park; Donald C Lo; Guy S Salvesen; Lisa M Ellerby; Jonathan A Ellman
Journal:  Chem Biol       Date:  2010-11-24

2.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

Review 3.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

Review 4.  The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.

Authors:  Ravi Chopra; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 5.  Developmental origins of cortical hyperexcitability in Huntington's disease: Review and new observations.

Authors:  Carlos Cepeda; Katerina D Oikonomou; Damian Cummings; Joshua Barry; Vannah-Wila Yazon; Dickson T Chen; Janelle Asai; Christopher K Williams; Harry V Vinters
Journal:  J Neurosci Res       Date:  2019-07-28       Impact factor: 4.164

Review 6.  The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Authors:  David Blum; Yijuang Chern; Maria Rosaria Domenici; Luc Buée; Chien-Yu Lin; William Rea; Sergi Ferré; Patrizia Popoli
Journal:  J Caffeine Adenosine Res       Date:  2018-06-01

7.  BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice.

Authors:  A Reiner; H B Wang; N Del Mar; K Sakata; W Yoo; Y P Deng
Journal:  Brain Res       Date:  2012-07-20       Impact factor: 3.252

8.  Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms.

Authors:  Jennifer Bradford; Ji-Yeon Shin; Meredith Roberts; Chuan-En Wang; Xiao-Jiang Li; Shihua Li
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-11       Impact factor: 11.205

9.  Rescuing the Corticostriatal Synaptic Disconnection in the R6/2 Mouse Model of Huntington's Disease: Exercise, Adenosine Receptors and Ampakines.

Authors:  Carlos Cepeda; Damian M Cummings; Miriam A Hickey; Max Kleiman-Weiner; Jane Y Chen; Joseph B Watson; Michael S Levine
Journal:  PLoS Curr       Date:  2010-09-20

10.  Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration.

Authors:  F Cicchetti; S Saporta; R A Hauser; M Parent; M Saint-Pierre; P R Sanberg; X J Li; J R Parker; Y Chu; E J Mufson; J H Kordower; T B Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.